It is well-established that NAbs emerge in most patients within a few months following HIV infection and that the NAbs developed by individual patients primarily target the autologous virus. However HIV+ sera can also neutralize heterologous isolates (cross-neutralizing antibody responses). The epitope-specificity of these cross-neutralizing antibody responses is largely unknown. We examined HIV+ antiretroviral-naive patients and identified a small number of subjects that developed broad anti-HIV plasma cross-neutralizing antibody responses. The plasma of one patient neutralizes all isolated tested against, irrespective of clade. Epitope- mapping analysis indicated that the exceptionally broad plasma neutralizing activity of that subject is exclusively due to anti-CD4-BS antibodies. However, because most patients, irrespective of the breadth of their plasma cross-neutralizing antibody responses, develop anti- CD4-BS antibodies, we hypothesize that the epitope(s) recognized by that patient's anti-CD4- BS antibodies differ from those recognized by the anti-CD4-BS antibodies of most HIV+- patients. We propose to isolate and characterize anti-CD4-BS MAbs from that patient and also to examine how the virus manages to escape their action. We have also identified another patient that developed 4E10-like and 2F5-like antibodies. We propose to map the precise epitope of these antibodies and examine the viral determinants of escape from those antibodies in that patient. In most cases, however, we were unable to map the epitope-specificities of broad plasma cross-neutralizing antibody responses to a particular epitope on Env. Our proposed studies aim at identifying the epitopes recognized by broadly cross-reactive NAbs developed during natural HIV-infection. This analysis will provide insights into the pathways that lead to the development of cross-reactive NAbs during HIV-infection, their epitopes, and the determinants of viral-escape from broadly-cross-reactive NAbs. Information from such studies can be used to develop more effective immunogens.

Public Health Relevance

Our proposed studies aim at improving our understanding of the interaction between HIV and the immune system, specifically with B cell mediated neutralizing antibody responses. Such studies are significant since they will provide new information on the mechanisms of HIV- mediated pathogenesis that leads to AIDS.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI081625-05
Application #
8602795
Study Section
AIDS Immunology and Pathogenesis Study Section (AIP)
Program Officer
Lawrence, Diane M
Project Start
2010-01-01
Project End
2014-12-31
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
5
Fiscal Year
2014
Total Cost
$438,731
Indirect Cost
$142,233
Name
Seattle Biomedical Research Institute
Department
Type
DUNS #
070967955
City
Seattle
State
WA
Country
United States
Zip Code
98109
Cohen, Kristen; Altfeld, Marcus; Alter, Galit et al. (2014) Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection. J Virol 88:13310-21
Dugast, Anne-Sophie; Stamatatos, Leonidas; Tonelli, Andrew et al. (2014) Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection. Eur J Immunol 44:2925-37
Jardine, Joseph; Julien, Jean-Philippe; Menis, Sergey et al. (2013) Rational HIV immunogen design to target specific germline B cell receptors. Science 340:711-6
Hoot, Sam; McGuire, Andrew T; Cohen, Kristen W et al. (2013) Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog 9:e1003106
McGuire, Andrew T; Hoot, Sam; Dreyer, Anita M et al. (2013) Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J Exp Med 210:655-63
Diskin, Ron; Klein, Florian; Horwitz, Joshua A et al. (2013) Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies. J Exp Med 210:1235-49
Mikell, Iliyana; Sather, D Noah; Kalams, Spyros A et al. (2011) Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog 7:e1001251